- Home
- SID vs NVCR Comparison
SID vs NVCR Comparison
Compare SID & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SID
- NVCR
- Stock Information
- Founded
- SID 1941
- NVCR 2000
- Country
- SID Brazil
- NVCR Switzerland
- Employees
- SID N/A
- NVCR N/A
- Industry
- SID Steel/Iron Ore
- NVCR Medical/Dental Instruments
- Sector
- SID Industrials
- NVCR Health Care
- Exchange
- SID Nasdaq
- NVCR Nasdaq
- Market Cap
- SID 2.0B
- NVCR 1.9B
- IPO Year
- SID 1997
- NVCR 2015
- Fundamental
- Price
- SID $1.63
- NVCR $17.00
- Analyst Decision
- SID Strong Sell
- NVCR Strong Buy
- Analyst Count
- SID 3
- NVCR 4
- Target Price
- SID $2.40
- NVCR $37.50
- AVG Volume (30 Days)
- SID 2.5M
- NVCR 732.5K
- Earning Date
- SID 05-07-2025
- NVCR 04-24-2025
- Dividend Yield
- SID 13.71%
- NVCR N/A
- EPS Growth
- SID N/A
- NVCR N/A
- EPS
- SID N/A
- NVCR N/A
- Revenue
- SID $7,063,567,739.00
- NVCR $605,220,000.00
- Revenue This Year
- SID $8.50
- NVCR $3.11
- Revenue Next Year
- SID $5.05
- NVCR $10.61
- P/E Ratio
- SID N/A
- NVCR N/A
- Revenue Growth
- SID N/A
- NVCR 18.82
- 52 Week Low
- SID $1.27
- NVCR $11.70
- 52 Week High
- SID $3.08
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- SID 47.91
- NVCR 31.91
- Support Level
- SID $1.60
- NVCR $18.23
- Resistance Level
- SID $1.71
- NVCR $19.06
- Average True Range (ATR)
- SID 0.06
- NVCR 0.70
- MACD
- SID -0.02
- NVCR -0.07
- Stochastic Oscillator
- SID 10.87
- NVCR 1.66
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. The company operate throughout the entire steel production chain, from the mining of iron ore to the production and sale of a diversified range of steel products. It operates in five segments namely, Steel, Mining, Logistics, Energy, and Cement. It generates maximum revenue from the steel segment. Geographically, it derives a majority of revenue from Asia.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.